Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials

Journal of Clinical Oncology

Volumn 18, Issue 8, 2000, Pages 1733-1739

  Rustin, Gordon J S ^a   Nelstrop, Ann E ^a   Bentzen, Soøren M ^a   Bond, Simon J ^a   McClean, Patrick ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CALCITRIOL; CISPLATIN; DOCETAXEL; ETOPOSIDE; FOSQUIDONE; GEMCITABINE; ISOTRETINOIN; OXALIPLATIN; PACLITAXEL; RALTITREXED; RHIZOXIN; TALLIMUSTINE; TOPOTECAN; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CROSSOVER PROCEDURE; DISEASE COURSE; FEMALE; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033994678     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.8.1733     Document Type: Article

References (27)

1. Bast RC, Klug TL, John ES, et al: A radioimmunoassay using monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883-887, 1983
2. Tuxen MK, Soletormost G, Dombernowsky P: Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 21:215-245, 1995
3. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
4. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
5. Rustin GJS, Nelstrop AE, McClean P, et al: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125. J Clin Oncol 14:1545-1551, 1996
6. Rustin GJS, Nelstrop AE, Bentzen SM, et al: Use of tumor markers in monitoring the course of ovarian cancer. Ann Oncol 10:S21-S27, 1999 (suppl 1)
7. Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353, 1961
8. Markman M, Hoskins W: Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol 10:513-514, 1992
9. Piccart MJ, Gore M, Ten Bokkel Huinink W, et al: Docetaxel: An active new drug for the treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87:676-681, 1995
10. Piccart MJ, Rustin GJS, Gore ME, et al: Docetaxel in platinum-pretreated patients, in Sharp F, Blackett T, Leake R, et al (eds): Ovarian Cancer (vol 4). London, United Kingdom, Chapman & Hall, 1996, pp 153-163
11. Rustin GJS, Nelstrop AE, Crawford M, et al: Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA-125. J Clin Oncol 15:172-176, 1997
12. Kaye SB, Wanders J, Clavel M, et al: Phase II trials of fosquidone (GR63178A) in carcinoma of the breast, head and neck, ovary and melanoma. Ann Oncol 3:406-408, 1992
13. Kerr DJ, Rustin GJ, Kaye SB, et al: Phase II trials of rhizoxin in advance ovarian, colorectal and renal cancer. Brit J Cancer 72:1267-1269, 1995
14. Gore M, Earl HM, Cassidy J, et al: A phase II study of Tomudex in relapsed epithelial ovarian cancer. Ann Oncol 6:724-725, 1995
15. Rustin GJS, Quinnell TG, Johnson J, et al: Trial of Isotretinoin and Calcitriol monitored by CA 125 in patients with ovarian cancer. Brit J Cancer 74:1479-1481, 1996
16. Bridgewater JA, Nelstrop AE, Rustin GJS, et al: Comparison of standard and CA-125 response criteria in patients with epithelialovarian cancer treated with platinum or paclitaxel. J Clin Oncol 17:501-508, 1999
17. Morgan RJ, Speyer J, Doroshow JH, et al: Modulation of 5-fluorouracil with high-dose leucovorin calcium: Activity in ovarian cancer and correlation with CA 125 levels. Gynecol Oncol 58:79-85, 1995
18. Hoskins PJ, Swenerton KD: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60-63, 1996
19. Underhill C, Parnis FX, Highley M, et al: A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC). Ann Oncol 7:69, 1996 (abstr) (suppl 5)
20. Neijt JP, Kaufman M, Bauknecht T, et al: Gemcitabine in pretreated ovarian cancer. Ann Oncol 7:70, 1996 (abstr) (suppl 5)
21. Piccart-Gebhart M, Green J, Lacave A, et al: A randomized phase II study of taxol or oxaliplatin in platinum-pretreated epithelial ovarian cancer patients. Proc Am Soc Clin Oncol 17:349, 1998 (abstr 1347)
22. Gore M, Levy V, Rustin G, et al: Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: The UK and Eire experience. Brit J Cancer 72:1016-1019, 1995
23. Eisenhauer E, ten Bokkel Huinink W, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
24. ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
25. Vermorken JB, Huijskes RVHP, Hoekman K, et al: Clinical (WHO) and serum tumour marker (CA125) response to platinum based chemotherapy after ovarian cancer (OVCA). Eur J Cancer 31A:S110, 1996 (abstr) (suppl 5)
26. Bolis G, Malstrom H, Mangioni J, et al: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group Trial. Ann Oncol 5:68, 1996 (abstr) (suppl)
27. Creemors GJ, Bolis G, Scarfone G, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14:3056-3061, 1996